Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.54 |
| ▸ | AURKA | O14965 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | MERTK | Q12866 | 1/20 | 0.45 |
| ▸ | TEK | Q02763 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12789817 | 0.80 | ALDH1A1 (0.75) | AURKAALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL6203559 | 0.76 | ALDH1A1 (0.66) | AURKAALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL6203768 | 0.76 | ALDH1A1 (0.66) | AURKAALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL6204604 | 0.74 | ALDH1A1 (0.59) | AURKAALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL6202165 | 0.72 | ALDH1A1 (0.51) | AURKAALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL6198425 | 0.72 | AURKA (0.52) | AURKAALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL756703 | 0.72 | AURKA (0.80) | AURKAEGFRMERTK | |
| SCHEMBL6200494 | 0.71 | AURKA (0.71) | GSK3BAURKAALDH1A1HPGDTSHR | |
| SCHEMBL6248624 | 0.69 | WDR5 (0.45) | AURKAALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL31667944 | 0.69 | EGFR (0.80) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1425283-B1 | NOVEL 4-AMINOFUROPYRIMIDINES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040259888-A1 | Novel 4-aminofuropyrimidines and the use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259888-A1 | Novel 4-aminofuropyrimidines and the use thereof | DPYD, TPMT, TYMP | GSK3B 3725/4885AURKA 795/4885ALDH1A1 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.